Formae

Pharmaceutical companies sighed with relief on Wednesday after US President Donald Trump has shown that they would not be subject to mutual tariffs – but this resentment may be fleeting if the White House moves forward with plans for the sector.

Trump administration considers the possibility of launching a so -called 232 pharmaceutical investigation among other branches that may lead to duty quoted A senior administration official was on Wednesday.

The White House did not immediately respond to CNBC’s request for confirmation.

“Pharmaceutical companies are going to go back, they are coming back, they all return to our country because if they fail to pay a big tax. And if they do it, I will be very happy,” Trump said during his tariff announcement.

In the National Extraordinary Declaration, which accompanies the tariff plan, the White House led “particularly acute” need to strengthen domestic production in various sectors, such as pharmaceuticals, autos and shipbuilding.

The healthcare reserves opened just above Thursday, but the STOXX healthcare index then fell 0.4% to 11:00 in London time, continuing the loss from the previous session when investors were involved in greater uncertainty.

Switzerland Rosh The LED decreases by pouring 2.4%, while the Wegovy Novo manufacturer decreased by 0.7%. Other regional players including Novartis. Bavarian northern. Astrazeneca Specified slightly higher.

Hope pharmaceutical confirmed This post will soon come but since then the drug manufacturers lobby for the administration for a phased approach To allow companies to move their production states.

“The whisper, the potential for the phase approach, when it materializes, can mitigate immediate shocks in the industry,” City said on Thursday.

However, even with a delayed approach, the complex nature of the pharmaceutical chains of supply means that “big changes are on a long time scale”, making any help potentially short -lived.

Novo nordisk On Thursday, he refused to comment on the tariff developments, but last week, Chairman Helge Lund told CNBC that the company did not reflect on any collection announcement and instead focused on being “flexible”.

Novo Nordisk already has a significant American production, which, according to Lund, is “expanding”, but it will not comment on sales in the United States obtained from American plants, as well as the possible impact of the Wegovy drug prices.

On Thursday, Rosh said the US has a complete pharmaceutical and diagnosis, which operates 25,000 employees, but added that “considering additional investments in the US to continue to meet the needs of patients.”

The British Astrazeneca drug manufacturer has refused to comment on further sectors.

Meanwhile, Danish Biotech Novones, which has a significant mark on the US, said on Tuesday CNBC that “uncertainty” around the tariff strategy is likely to stop investment and consumer demand.

“It causes uncertainty, and if you are uncertain, you stop. You suspend the innovation, you publish, you suspend the investment,” she said.